LPV/RTV

DRUG3 trials

Sponsors

Tibotec Pharmaceuticals, Ireland, ViiV Healthcare

Conditions

HIVHIV InfectionHIV Infections

Phase 3

TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients

CompletedNCT00110877

Tibotec Pharmaceuticals, IrelandHIV Infection

Start: 2005-04-30End: 2011-10-31Updated: 2015-07-03

TMC114-C211: Trial of an Investigational Protease Inhibitor TMC114 With Ritonavir (TMC114/r) in HIV-1 Infected Patients Who Have Never Been Treated With Antiretroviral Medications.

CompletedNCT00258557

Tibotec Pharmaceuticals, IrelandHIV

Start: 2005-09-30End: 2012-05-31Updated: 2013-06-26

Comparative Efficacy and Safety Study of Dolutegravir and Lopinavir/Ritonavir in Second-line Treatment

CompletedNCT02227238

ViiV HealthcareHIV Infections

Start: 2014-12-11End: 2022-02-14Updated: 2023-03-13

Related Papers

Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study.

2021-10-2528 citations

Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial.

2019-02-04147 citations

HIV-1 resistance rarely observed in patients using darunavir once-daily regimens across clinical studies.

2017-11-1632 citations

Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial.

2012-10-23127 citations